2,051 Shares in BioNTech SE (NASDAQ:BNTX) Purchased by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,051 shares of the company’s stock, valued at approximately $244,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Candriam S.C.A. grew its position in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after acquiring an additional 341,311 shares in the last quarter. SG Americas Securities LLC boosted its stake in BioNTech by 610.5% during the 1st quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after acquiring an additional 60,270 shares during the last quarter. Acadian Asset Management LLC grew its holdings in BioNTech by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock worth $10,275,000 after acquiring an additional 37,792 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of BioNTech in the 2nd quarter valued at about $2,892,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BNTX has been the subject of a number of research reports. HC Wainwright lifted their price target on BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. JPMorgan Chase & Co. upgraded BioNTech from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $91.00 to $125.00 in a research report on Monday, September 16th. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Bank of America lifted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Finally, TD Cowen increased their target price on shares of BioNTech from $85.00 to $132.00 and gave the stock a “hold” rating in a report on Monday, October 21st. Five analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $135.54.

BioNTech Stock Performance

BNTX opened at $110.48 on Monday. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $107.26 and its 200-day moving average is $94.98. The stock has a market cap of $26.26 billion, a PE ratio of 220.96 and a beta of 0.24. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same period in the previous year, the firm earned ($0.86) EPS. The firm’s revenue was down 23.3% on a year-over-year basis. On average, analysts predict that BioNTech SE will post -3.04 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.